322 466

Cited 0 times in

조기 류마티스관절염의 약물치료

DC Field Value Language
dc.contributor.author박민찬-
dc.contributor.author이수곤-
dc.date.accessioned2015-07-15T17:14:38Z-
dc.date.available2015-07-15T17:14:38Z-
dc.date.issued2003-
dc.identifier.issn1975-8456-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/114518-
dc.description.abstractThe past decade has greatly enhanced our understanding of rheumatoid arthritis (RA). Not only have new drug therapies become available, but this period has witnessed dramatic changes in treatment strategies as well. Since 1989, when the proposal on reversing the pyramid approach (the stepdown bridge concept) was published, the concept of early and aggressive treatment of RA has become the leading paradigm. The theory underlying this approach is based on a better understanding of the devastating long term consequences of RA in most patients, and the logical tenet that irreversible damage must be prevented before it occurs. Evidence has shown the irreversible joint damage in RA occurs early in the disease, making a "wait and see" approach unacceptable. Thus, it appears logical to begin treatment as soon as a diagnosis of RA is confirmed, to slow disease progression by treatment with disease modifying antirheumatic drugs. This review will address the evidence supporting the benefit and the principles of early treatment, as well as the current update on pharmacological management in early RA.-
dc.description.statementOfResponsibilityopen-
dc.format.extent965~971-
dc.languageJOURNAL OF THE KOREAN MEDICAL ASSOCIATION-
dc.publisherJOURNAL OF THE KOREAN MEDICAL ASSOCIATION-
dc.relation.isPartOfJOURNAL OF THE KOREAN MEDICAL ASSOCIATION-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHRheumatoid arthritis-
dc.subject.MESHEarly treatment-
dc.subject.MESHPharmacological management-
dc.subject.MESHDisease modifying antirheumatic drug-
dc.title조기 류마티스관절염의 약물치료-
dc.title.alternativeParadigm Shifting to Early Treatment of Rheumatoid Arthritis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthor박민찬-
dc.contributor.googleauthor이수곤-
dc.identifier.doi10.5124/jkma.2003.46.11.965-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01470-
dc.contributor.localIdA02889-
dc.relation.journalcodeJ01833-
dc.identifier.eissn2093-5951-
dc.identifier.pmid10.5124/jkma.2003.46.11.965-
dc.subject.keywordRheumatoid arthritis-
dc.subject.keywordEarly treatment-
dc.subject.keywordPharmacological management-
dc.subject.keywordDisease modifying antirheumatic drug-
dc.contributor.alternativeNamePark, Min Chan-
dc.contributor.alternativeNameLee, Soo Kon-
dc.contributor.affiliatedAuthorPark, Min Chan-
dc.contributor.affiliatedAuthorLee, Soo Kon-
dc.rights.accessRightsfree-
dc.citation.volume46-
dc.citation.number11-
dc.citation.startPage965-
dc.citation.endPage971-
dc.identifier.bibliographicCitationJOURNAL OF THE KOREAN MEDICAL ASSOCIATION, Vol.46(11) : 965-971, 2003-
dc.identifier.rimsid43902-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.